{"id":"ranibizumab-and-aflibercept","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Conjunctival hemorrhage"},{"rate":"5-15","effect":"Eye pain or discomfort"},{"rate":"5-10","effect":"Floaters"},{"rate":"5-10","effect":"Increased intraocular pressure"},{"rate":"0.1-0.5","effect":"Endophthalmitis (infection)"},{"rate":"0.1-1","effect":"Retinal detachment"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Both drugs bind to and neutralize VEGF-A, a key driver of pathological neovascularization and vascular permeability in retinal diseases. By blocking VEGF signaling, they reduce fluid accumulation, prevent new vessel formation, and stabilize or improve vision in conditions characterized by retinal vascular dysfunction. Ranibizumab is a humanized monoclonal antibody fragment, while aflibercept is a soluble VEGF receptor fusion protein.","oneSentence":"Ranibizumab and aflibercept are anti-VEGF agents that inhibit vascular endothelial growth factor to reduce abnormal blood vessel growth and leakage in the retina.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:03:55.848Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neovascular (wet) age-related macular degeneration"},{"name":"Diabetic macular edema"},{"name":"Retinal vein occlusion"},{"name":"Diabetic retinopathy"}]},"trialDetails":[{"nctId":"NCT05407636","phase":"PHASE3","title":"Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD","status":"RECRUITING","sponsor":"AbbVie","startDate":"2022-01-13","conditions":"AMD, nAMD, Wet Age-related Macular Degeneration","enrollment":660},{"nctId":"NCT06985706","phase":"PHASE3","title":"Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns","status":"RECRUITING","sponsor":"Belfast Health and Social Care Trust","startDate":"2025-05-19","conditions":"Severe Diabetic Macular Oedema","enrollment":264},{"nctId":"NCT03832179","phase":"PHASE4","title":"Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification","status":"COMPLETED","sponsor":"Bay Area Retina Associates","startDate":"2018-11-15","conditions":"Diabetic Macular Edema, Cataract","enrollment":16},{"nctId":"NCT07009574","phase":"","title":"The Treatment Burden of Myopic Choroidal Neovascularization","status":"NOT_YET_RECRUITING","sponsor":"Policlinico Gaspare Rodolico - San Marco Catania","startDate":"2025-06-01","conditions":"Myopic Choroidal Neovascularisation, Anti-VEGF Treatment, Burden","enrollment":100},{"nctId":"NCT03585556","phase":"PHASE1","title":"AAVCAGsCD59 for the Treatment of Wet AMD","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-09-13","conditions":"Wet Age-related Macular Degeneration","enrollment":25},{"nctId":"NCT02397954","phase":"PHASE2","title":"A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2015-03-12","conditions":"Idiopathic Polypoidal Choroidal Vasculopathy","enrollment":4},{"nctId":"NCT05571267","phase":"PHASE2","title":"Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD","status":"TERMINATED","sponsor":"IVERIC bio, Inc.","startDate":"2016-10-20","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":1},{"nctId":"NCT05640895","phase":"","title":"Intravitreal Injection Site and Perceived Pain","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2022-11-14","conditions":"Pain","enrollment":53},{"nctId":"NCT02669953","phase":"","title":"Aflibercept in Recurrent or Persistent CNV","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2015-12","conditions":"Age Related Macular Degeneration, Intravitreal Injections, Diabetic Macular Edema","enrollment":80},{"nctId":"NCT02387957","phase":"PHASE2","title":"A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2016-04-26","conditions":"Age-Related Macular Degeneration","enrollment":63},{"nctId":"NCT03709745","phase":"PHASE4","title":"Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion","status":"COMPLETED","sponsor":"St. Erik Eye Hospital","startDate":"2018-10-18","conditions":"Branch Retinal Vein Occlusion with Macular Edema","enrollment":110},{"nctId":"NCT03630315","phase":"PHASE1","title":"CLN-0046: Treatment of AMD Subjects With OTX-TKI","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2019-02-18","conditions":"Neovascular Age-related Macular Degeneration","enrollment":29},{"nctId":"NCT04662944","phase":"","title":"A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-02-23","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":494},{"nctId":"NCT05211804","phase":"","title":"Mechanisms of Retinal Revascularization and Clinical Indicators of Neovascular AMD Relapse","status":"COMPLETED","sponsor":"Sorlandet Hospital HF","startDate":"2022-02-08","conditions":"Wet Macular Degeneration","enrollment":31},{"nctId":"NCT02214628","phase":"PHASE2","title":"Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2014-07","conditions":"Age-related Macular Degeneration","enrollment":101},{"nctId":"NCT06231121","phase":"","title":"Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2023-12-01","conditions":"Neovascular Age-related Macular Degeneration","enrollment":13},{"nctId":"NCT05126966","phase":"PHASE3","title":"A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2023-12-29","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":""},{"nctId":"NCT06205979","phase":"EARLY_PHASE1","title":"Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2023-12-12","conditions":"Diabetic Macular Edema","enrollment":50},{"nctId":"NCT02559180","phase":"PHASE4","title":"Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab","status":"COMPLETED","sponsor":"Rishi Singh","startDate":"2015-10","conditions":"Diabetic Retinopathy, Macular Edema","enrollment":20},{"nctId":"NCT02157077","phase":"PHASE3","title":"Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2013-12","conditions":"Macular Degeneration, Wet Macular Degeneration, Retinal Degeneration","enrollment":90},{"nctId":"NCT04698850","phase":"PHASE4","title":"Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation","status":"WITHDRAWN","sponsor":"Faculty Hospital Kralovske Vinohrady","startDate":"2021-01-04","conditions":"Wet Macular Degeneration","enrollment":""},{"nctId":"NCT05282420","phase":"PHASE4","title":"Ranibizumab Versus Aflibercept for CRVO in Young Patients.","status":"UNKNOWN","sponsor":"South Valley University","startDate":"2021-02-01","conditions":"Non-Ischemic Central Retinal Vein Occlusion With Macular Edema","enrollment":40},{"nctId":"NCT02348359","phase":"PHASE2","title":"X-82 to Treat Age-related Macular Degeneration","status":"TERMINATED","sponsor":"Tyrogenex","startDate":"2015-03-16","conditions":"Age-Related Macular Degeneration (AMD), Macular Degeneration, Exudative Age-related Macular Degeneration","enrollment":157},{"nctId":"NCT05222633","phase":"","title":"Anti-VEGF in Real-world","status":"UNKNOWN","sponsor":"Wenbin Wei","startDate":"2022-01-01","conditions":"Neovascular Age-related Macular Edema, Diabetic Macular Edema, Choroidal Neovascular Membrane","enrollment":1000},{"nctId":"NCT05186155","phase":"","title":"Analysis of Ocular and Neurodevelopmental Function for Retinopathy of Prematurity","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2019-01-01","conditions":"Retinopathy of Prematurity, Neurodevelopmental Abnormality","enrollment":510},{"nctId":"NCT05110209","phase":"","title":"Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-07-15","conditions":"Age-related Macular Degeneration (AMD)","enrollment":331541},{"nctId":"NCT05146687","phase":"","title":"Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-07-15","conditions":"Age-related Macular Degeneration (AMD)","enrollment":369600},{"nctId":"NCT02174211","phase":"NA","title":"A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy.","status":"COMPLETED","sponsor":"King's College Hospital NHS Trust","startDate":"2014-06","conditions":"Age Related Macular Degeneration","enrollment":59},{"nctId":"NCT04836143","phase":"","title":"Eyes That Do Not Meet the Eligibility Criteria of Clinical Trials on Age-Related Macular Degeneration: Proportion of the Real-World Patient Population and Reasons for Exclusion","status":"COMPLETED","sponsor":"Kim's Eye Hospital","startDate":"2019-08-26","conditions":"Age-related Macular Degeneration","enrollment":512},{"nctId":"NCT04245072","phase":"NA","title":"Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Central Chorioretinitis","status":"UNKNOWN","sponsor":"The Filatov Institute of Eye Diseases and Tissue Therapy","startDate":"2018-03-27","conditions":"Chorioretinitis","enrollment":100},{"nctId":"NCT02274259","phase":"PHASE4","title":"Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen","status":"COMPLETED","sponsor":"Anders Kvanta","startDate":"2014-10","conditions":"Central Retinal Vein Occlusion","enrollment":40},{"nctId":"NCT03423823","phase":"PHASE2","title":"Ziv-aflibercept Efficacy in Better Regulating AMD","status":"COMPLETED","sponsor":"Kapil Kapoor","startDate":"2017-07-07","conditions":"Wet Macular Degeneration, Wet Age-related Macular Degeneration","enrollment":62},{"nctId":"NCT01627249","phase":"PHASE3","title":"Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2012-08","conditions":"Diabetic Macular Edema","enrollment":660},{"nctId":"NCT04087746","phase":"PHASE4","title":"Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema (DME)","status":"COMPLETED","sponsor":"Minia University","startDate":"2017-01","conditions":"Diabetic Macular Edema","enrollment":400},{"nctId":"NCT02457975","phase":"EARLY_PHASE1","title":"Photobiomodulation for the Treatment of Diabetic Macular Edema","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2015-06","conditions":"Diabetic Retinopathy","enrollment":16},{"nctId":"NCT04018833","phase":"","title":"Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Bernardete Pessoa MD","startDate":"2012-01-01","conditions":"Diabetic Macular Edema, Diabetic Retinopathy","enrollment":40},{"nctId":"NCT03999125","phase":"PHASE4","title":"Anti-VEGF Therapy Versus Dexamethasone Implant for DME","status":"UNKNOWN","sponsor":"Sudhalkar Eye Hospital","startDate":"2019-06-25","conditions":"Clinically Significant Macular Edema Due to Diabetes Mellitus","enrollment":150},{"nctId":"NCT02130024","phase":"PHASE4","title":"A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-04-11","conditions":"Age-Related Macular Degeneration","enrollment":281},{"nctId":"NCT03975088","phase":"NA","title":"Sub-macular Injection of Ranibizumab as a New Surgical Treatment for Refractory Diabetic Macular Edema","status":"COMPLETED","sponsor":"University of Alexandria","startDate":"2017-01-01","conditions":"Diabetic Macular Edema","enrollment":19},{"nctId":"NCT03340610","phase":"PHASE4","title":"IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab","status":"COMPLETED","sponsor":"Southeast Retina Center, Georgia","startDate":"2015-06","conditions":"Diabetic Macular Edema","enrollment":30},{"nctId":"NCT02257632","phase":"PHASE4","title":"Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-04-08","conditions":"Wet Age-Related Macular Degeneration","enrollment":41},{"nctId":"NCT02363621","phase":"PHASE2","title":"Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME","status":"COMPLETED","sponsor":"Arshad Khanani","startDate":"2015-01","conditions":"Diabetic Macular Edema","enrollment":101},{"nctId":"NCT01918371","phase":"","title":"A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-08-02","conditions":"Retinal Vein Occlusion, Macular Edema","enrollment":323},{"nctId":"NCT01958918","phase":"PHASE4","title":"Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-10-23","conditions":"Neovascular Age-related Macular Degeneration","enrollment":712},{"nctId":"NCT02471651","phase":"PHASE4","title":"Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema","status":"COMPLETED","sponsor":"California Retina Consultants","startDate":"2015-06","conditions":"Diabetic Macular Edema","enrollment":40},{"nctId":"NCT02161575","phase":"PHASE4","title":"Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-08-28","conditions":"Neovascular Age-related Macular Degeneration","enrollment":103},{"nctId":"NCT01972763","phase":"PHASE1, PHASE2","title":"Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.","status":"COMPLETED","sponsor":"Northern California Retina Vitreous Associates","startDate":"2013-10","conditions":"Recalcitrant Wet Age-related Macular Degeneration","enrollment":12},{"nctId":"NCT02309281","phase":"PHASE4","title":"Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab","status":"COMPLETED","sponsor":"Vista Klinik","startDate":"2013-05","conditions":"Neovascular Age-related Macular Degeneration","enrollment":33},{"nctId":"NCT02218177","phase":"","title":"Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2014-08","conditions":"Age Related Macular Degeneration","enrollment":30},{"nctId":"NCT02591914","phase":"PHASE1","title":"An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Retinal Consultants of Arizona","startDate":"2014-02","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":30},{"nctId":"NCT01617148","phase":"PHASE4","title":"Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept","status":"COMPLETED","sponsor":"Rishi Singh","startDate":"2012-06","conditions":"Exudative Macular Degeneration","enrollment":26},{"nctId":"NCT03324542","phase":"","title":"Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macular Degeneration in Taiwan","status":"COMPLETED","sponsor":"Changhua Christian Hospital","startDate":"2017-04-03","conditions":"AMD","enrollment":63},{"nctId":"NCT02321241","phase":"","title":"Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-01","conditions":"Wet Macular Degeneration","enrollment":236},{"nctId":"NCT03059277","phase":"PHASE4","title":"Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab","status":"WITHDRAWN","sponsor":"Southeast Clinical Research Associates, LLC","startDate":"2018-06-01","conditions":"Diabetic Macular Edema","enrollment":""},{"nctId":"NCT01712035","phase":"","title":"Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2012-10","conditions":"Neovascular Age-related Macular Degeneration","enrollment":44},{"nctId":"NCT02321267","phase":"PHASE4","title":"Cohort Study of the Clinical Course of Macular Diseases in Kagawa","status":"UNKNOWN","sponsor":"Kagawa University","startDate":"2014-12","conditions":"Macular Disease","enrollment":1000},{"nctId":"NCT02291887","phase":"","title":"Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept","status":"COMPLETED","sponsor":"Associated Retinal Consultants, Michigan","startDate":"2014-12-22","conditions":"Age-Related Macular Degeneration","enrollment":13},{"nctId":"NCT03038048","phase":"NA","title":"30g vs 33g Needle for Intravitreal Injections","status":"COMPLETED","sponsor":"Wills Eye","startDate":"2017-01-27","conditions":"Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion","enrollment":50},{"nctId":"NCT01988662","phase":"PHASE4","title":"UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-04","conditions":"Neovacular Age-related Macular Degeneration","enrollment":205},{"nctId":"NCT02878681","phase":"PHASE4","title":"24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2016-09","conditions":"Visual Impairment Due to Diabetic Macular Edema","enrollment":""},{"nctId":"NCT02634970","phase":"PHASE4","title":"CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2016-03","conditions":"Wet Age-related Macular Degeneration (Wet AMD)","enrollment":""},{"nctId":"NCT01543568","phase":"PHASE4","title":"Study for Recalcitrant Age Related Macular Degeneration","status":"COMPLETED","sponsor":"David M. Brown, M.D.","startDate":"2012-02","conditions":"Age Related Macular Degeneration","enrollment":46},{"nctId":"NCT02258009","phase":"PHASE4","title":"Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2015-10","conditions":"Visual Impairment Due to Diabetic Macular Edema","enrollment":""},{"nctId":"NCT01414153","phase":"PHASE2","title":"Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD","status":"COMPLETED","sponsor":"Lpath, Inc.","startDate":"2012-08","conditions":"Exudative Age-related Macular Degeneration","enrollment":158},{"nctId":"NCT02081339","phase":"","title":"Cohort Study of the Clinical Course of Macular Diseases in Japanese","status":"UNKNOWN","sponsor":"Kyoto University, Graduate School of Medicine","startDate":"2014-03","conditions":"Macular Disease","enrollment":1000},{"nctId":"NCT01942213","phase":"","title":"Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients.","status":"COMPLETED","sponsor":"Prism Vision Group","startDate":"2013-12","conditions":"Neovascular Age Related Macular Degeneration","enrollment":136},{"nctId":"NCT02118831","phase":"PHASE1, PHASE2","title":"Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF","status":"COMPLETED","sponsor":"California Retina Consultants","startDate":"2012-03","conditions":"Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion","enrollment":56},{"nctId":"NCT01926977","phase":"PHASE1, PHASE2","title":"Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration","status":"COMPLETED","sponsor":"Arshad Khanani","startDate":"2013-09","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":100},{"nctId":"NCT02651168","phase":"PHASE4","title":"Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study","status":"UNKNOWN","sponsor":"Unity Health Toronto","startDate":"2016-03","conditions":"Diabetic Macular Edema","enrollment":50},{"nctId":"NCT02646670","phase":"PHASE4","title":"Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Instituto de Olhos de Goiania","startDate":"2015-07","conditions":"Retinal Diseases","enrollment":20},{"nctId":"NCT02641457","phase":"PHASE3","title":"Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis","status":"COMPLETED","sponsor":"Instituto de Olhos de Goiania","startDate":"2014-03","conditions":"Glaucoma, Rubeosis Iridis","enrollment":2},{"nctId":"NCT02296567","phase":"PHASE2, PHASE3","title":"Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients","status":"UNKNOWN","sponsor":"East Florida Eye Institute","startDate":"2014-12","conditions":"Age Related Macular Degeneration","enrollment":80},{"nctId":"NCT00637377","phase":"PHASE3","title":"Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-04","conditions":"Macular Degeneration","enrollment":1240},{"nctId":"NCT02000102","phase":"","title":"Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab","status":"COMPLETED","sponsor":"Stanford University","startDate":"2013-09","conditions":"Diabetic Macular Edema","enrollment":14},{"nctId":"NCT02126904","phase":"","title":"Comparison of the Time to Recurrence Between Ranibizumab and Aflibercept","status":"UNKNOWN","sponsor":"Yokohama City University Medical Center","startDate":"2012-01","conditions":"The Injection Burden","enrollment":200},{"nctId":"NCT01640171","phase":"NA","title":"Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival","status":"COMPLETED","sponsor":"Retina Vitreous Associates of Florida","startDate":"2012-07","conditions":"Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema","enrollment":57},{"nctId":"NCT00509795","phase":"PHASE3","title":"Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2007-08","conditions":"Macular Degeneration","enrollment":1217}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ranibizumab and Aflibercept","genericName":"Ranibizumab and Aflibercept","companyName":"Instituto de Olhos de Goiania","companyId":"instituto-de-olhos-de-goiania","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ranibizumab and aflibercept are anti-VEGF agents that inhibit vascular endothelial growth factor to reduce abnormal blood vessel growth and leakage in the retina. Used for Neovascular (wet) age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}